All In Biotech

Drug Trial Radar · NCT03987295

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9orf72 Mutations Causative of Frontotemporal Dementia

Last checked: Nov 19, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

33

Actual

Start

Sep 27, 2019

Primary completion

Jun 5, 2024

Study completion Jun 5, 2024

Sponsor

Lead sponsor
Alector Inc.Industry
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Jun 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.

Conditions

  • Frontotemporal Dementia

Interventions

  • AL001Drug

    60 mg/kg of AL001 every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Severity of TEAEsTime frame: 197 weeks
  2. Severity of Treatment-Related TEAEsTime frame: 197 weeks
  3. Any TEAE Leading to Study Drug DiscontinuationTime frame: 197 weeks
  4. Immunogenicity Antidrug Antibodies (ADA) TiterTime frame: 97 weeks
  5. Confirmatory Immunogenicity Antidrug Antibodies (ADA) ResponsesTime frame: 97 weeks
  6. Change From Baseline in Sheehan Suicidality Tracking ScaleTime frame: 197 weeks

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • UCSF

    San Francisco, California

  • Mayo Clinic

    Rochester, Minnesota

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases UT Health San Antonio

    San Antonio, Texas

  • Lawson Health Research Institute, St. Joseph's

    London, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Technical University of Munich

    München, Germany

  • University of Ulm

    Ulm, Germany

  • University of Brescia

    Brescia, Italy

  • Brain Research Center - PPDS

    Amsterdam, Netherlands

  • Erasmus University Medical Center

    Rotterdam, Netherlands

  • University College London

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.